Aileron Therapeutics, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.aileronrx.com

Market Cap $35.38M
Debt $NaN
Cash $17.65M
EV $NaN
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$29.24M
EBIT	-$29.61M
ROA	-28%
Growth Stability	1
PE	-1.21
Price/Cash	0.5
Equity CAGR	-5%
Earnings Growth YoY	220%
Earnings Growth QoQ	-35%
Equity CAGR 5Y	-4%

Equity CAGR 3Y	-19%
Market Cap	$35.38M
Revenue	$0.00
Assets	$104.22M
Cash	$17.65M
Shares Outstanding	16.69M
Working Capital	13.03M
Current Ratio	3.3
Shares Growth 3y	3%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects.

SEC Filings

Direct access to Aileron Therapeutics, Inc. (ALRN) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Aileron Therapeutics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Aileron Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Aileron Therapeutics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Aileron Therapeutics, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-	-	-	-	-	-	-	-
ROA	-	-83%	-44%	-105%	-113%	-125%	-55%	-126%	-15%	-28%
ROE	-	16%	-47%	-161%	-183%	-174%	-60%	-147%	-228%	-

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-	-	-	-	-
Earnings YoY growth	-	41%	24%	39%	-7%	-28%	24%	4%	-42%	-
Equity YoY growth	-	19%	-143%	-59%	-18%	-24%	261%	-58%	-63%	-4%
FCF YoY growth	-	-	-	56%	-18%	-23%	17%	-	-	-